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ABSTRACT
Patients on long-term hemodialysis are at very high risk for cardiovascular disease but are usually excluded from clinical
trials conducted in the general population or in at-risk populations. There are no universally agreed cardiovascular
outcomes for trials conducted speciﬁcally in the hemodialysis population. In this review, we highlight that trials reporting
cardiovascular outcomes in hemodialysis patients are usually of short duration (median 3 to 6 months) and are small
(59% of trials have <100 participants). Overall, the cardiovascular outcomes are very heterogeneous and may not reﬂect
outcomes that are meaningful to patients and clinicians in supporting decision making, as they are often surrogates
of uncertain clinical importance. Composite outcomes used in different trials rarely share the same components. In a ﬁeld
in which a single trial is often insufﬁciently powered to fully assess the clinical and economic impact of interventions,
differences in outcome reporting across trials make the task of meta-analysis and interpretation of all the available
evidence challenging. Core outcome sets are now being established across many specialties in health care to prevent
these problems. Through the global Standardized Outcomes in Nephrology–Hemodialysis initiative, cardiovascular
disease was identiﬁed as a critically important core domain to be reported in all trials in hemodialysis. Informed by
the current state of reporting of cardiovascular outcomes, a core outcome measure for cardiovascular disease is
currently being established with involvement of patients, caregivers, and health professionals. Consistent reporting
of cardiovascular outcomes that are critically important to hemodialysis patients and clinicians will strengthen
the evidence base to inform care in this very high-risk population. (J Am Coll Cardiol 2018;71:2802–10)
© 2018 by the American College of Cardiology Foundation.
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Humpty

(15). The value of trials to inform decision

ABBREVIATIONS

Dumpty said, in rather a scornful

making among patients, clinicians, and policy

AND ACRONYMS

hen

I

use

a

word,’

tone, ‘it means just what I choose

makers may also be reduced if the outcomes

it to mean—neither more nor less.’ ‘The question is,’

are selected on the basis of feasibility rather

said Alice, ‘whether you can make words mean so

than importance (16).

many different things.’” In writing Through the Look-

CVD = cardiovascular disease
MACE = major adverse cardiac
event(s)

The importance of choosing the right out-

ing Glass, Lewis Carroll (1) could have been referring

comes for clinical trials to inform decision making is

to cardiovascular outcomes reported in clinical trials,

widely accepted, but appropriate measurement of

particularly among patients on hemodialysis.

cardiovascular outcomes in trials can be challenging. In
particular, the major cardiovascular outcomes occur

CARDIOVASCULAR DISEASE

only in a relatively small fraction of participants

AND HEMODIALYSIS

meaning, unless trials are very large, follow-up periods

Worldwide, >2 million people have end-stage kidney
disease, with this number increasing annually by 5%
to 7% (2). Patients with end-stage kidney disease who
are treated with dialysis require a disproportionately
high amount of health care resources. The prevalence
of cardiovascular disease (CVD) in people on hemodialysis exceeds 60% (3,4) and accounts for >50% of
deaths (4–6). CVD mortality remains up to 30 times
higher in people on dialysis than in the general
population (6).

may need to be long in order to capture a sufﬁcient
number of speciﬁc events. This has led to an increasing
use of composite outcomes to increase the number
of events captured and to reduce sample size
requirements (17,18). When using composite endpoints, it is difﬁcult to estimate the true effect of an
intervention on different components of the composite,
particularly those that occur less frequently. Composites often combine outcomes with very different levels
of importance to patients, making interpretation of the
overall importance of the trial ﬁndings difﬁcult (18,19).

THE IMPORTANCE OF AN OUTCOME

Similarly, a compounding problem is that inclusion of
surrogates diverts attention from outcomes of more

Clinical trials of interventions designed to reduce

importance to patients and clinicians (20). Outcomes

CVD in patients with end-stage kidney disease

need to be relevant to all stakeholders, in particular the

have evaluated the use of medications (7–10) and the

patients within the speciﬁc disease group (21).

intensity and type of hemodialysis (11–13), but

The capacity to compare outcomes across trials

the results have generally not identiﬁed clear

and produce summary effect estimates through

evidence of beneﬁt. Such trials may have been less

meta-analysis would help improve conﬁdence in the

informative than possible because they were too

effects of interventions in the hemodialysis popula-

small to identify modest but realistic treatment

tion but would require that the outcomes be reported

effects. Inconsistencies in how cardiovascular out-

consistently.

comes were measured and reported made it difﬁcult
to compare the effectiveness of interventions across

THE NEED FOR CORE OUTCOME SETS

different trials or to combine trial results in metaanalyses (14). Reporting bias, both in terms of selec-

A core outcome set is an agreed standardized set

tive outcome reporting and publication bias, also has

of outcomes that should be measured and reported,

the potential to cause misinterpretation of evidence

as a minimum, in all clinical trials in the relevant

v
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F I G U R E 1 Search Results

Trials identified in
ClinicalTrials.gov
(to October 2016)
N = 418

Citations identified in Embase, Cochrane
specialized register, MEDLINE
(January 2011 to August 2016)
N = 1,390

Reasons for exclusion
Title and abstract
Study population not HD
No CVD outcomes
Nonrandomized
Completed prior to 2011
Unknown recruiting status
Duplicates
Open but not yet recruiting
Withdrawn/terminated
Systematic review

Trials excluded
N = 365

(N)
699
239
217
175
86
62
59
38
33
5

Citations excluded
N = 1,248

Publications included
N = 142
Trials included
N = 121

Trials included
N = 53

Total trials
N = 174
Participants = 148,730

Comprehensive search of MEDLINE, Embase, the Cochrane Kidney and Transplant Specialized Register, and ClinicalTrials.gov from 2011 to
2017 resulted in 174 randomized trials in patients on hemodialysis (HD) reporting at least 1 cardiovascular outcome. CVD ¼ cardiovascular
disease.

areas of health or health care (22). Recently, there

used in studies comparing bare-metal versus drug-

has been a proliferation of discipline-speciﬁc and

eluting stents found large-scale heterogeneity in the

global initiatives to develop core outcome sets

outcomes used (29). The use of “MACE” has become

(23,24). The Outcome Measures in Rheumatology

widespread, but the term is often used outside its

initiative was formed in 1992 and set the foundation

original context with a large number of varied outcome

for the development of core outcomes, speciﬁcally

measures used to make up the composite endpoint

in

rheumatology

(29). More recently, a number of core outcome sets

of

patients,

trials.

With

the

involvement
policy

have been developed for CVDs in speciﬁc populations,

makers, Outcome Measures in Rheumatology has

including a set for the effectiveness of cardiac surgery

improved the relevance of outcomes reported in

(30) and a set for pregnant women with CVD (31).

health

care

providers,

and

rheumatology trials. More recently, the Core Outcome
Measures
established

in

Effectiveness
to

facilitate

initiative

was

CURRENT STATE OF REPORTING OF CVD

development

and

OUTCOMES IN HEMODIALYSIS TRIALS

Trials
the

collation of core outcome sets across all diseases
A systematic search was conducted in MEDLINE,

internationally (23).
Among cardiovascular trialists, there have been
concerted

efforts

to

standardize

Embase,

the

Cochrane

Kidney

and

Transplant

cardiovascular

Specialized Register, and ClinicalTrials.gov for ran-

outcome reporting (25–27). Early attempts include the

domized controlled trials conducted in adults on

introduction of the term MACE, deﬁned as “major

hemodialysis (both published or in progress, from

adverse cardiac event(s),” in the mid-1990s, with its

2011 to 2017), which reported at least 1 cardiovascular

use theoretically restricted to in-hospital complica-

outcome (Online Table 1). We extracted a number of

tions related to percutaneous coronary interventions

trial characteristics as well as all cardiovascular

(28). However, the components of a MACE vary, even

outcome measures, including all levels of speciﬁca-

among trials of similar interventions. For example, a

tion (if reported), and the speciﬁc metric (e.g., time to

systematic review assessing the components of MACE

event, change from baseline), method of aggregation
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function or feel in relation to a health condition and

T A B L E 1 Characteristics of Included Trials (n ¼ 174)

its therapy, without interpretation by a health care

Number of Trials

%

0–49

64

38

50–99

35

21

100–499

49

29

Trial characteristics are presented in Table 1. Fifty-six

Participants

professional or anyone else (34).
TRIAL CHARACTERISTICS. We identiﬁed and included

174 trials involving 148,730 participants (Figure 1).

500–999

10

6

trials (32%) were unpublished. The published trials

1,000–4,999

9

5

were conducted across 28 countries, most frequently

$5,000

2

1

in Japan (8%) and the United States (8%), and 12 trials

Not stated

5

3

(7%) were multinational. The median trial duration

2011–2012

50

29

2013–2014

52

30

2015–2016

16

9

participants (interquartile range: 32 to 200 partici-

Not published

56

32

pants). It is of note that relative to many cardiovas-

Not stated

64

37

duration and the sample size are small. The most

Europe

43

25

common type of intervention was pharmacological

Asia

23

13

(103 trials [60%]). In 48 trials (27%), the intervention

United States

13

7

International

12

7

Middle East

11

6

Year of publication

was

15.0

months

(interquartile

range:

5.5

to

42.0 months), and the median sample size was 83

cular trials in the general population, both the trial

Region/country

South/Central America

4

2

Australasia

4

2

Duration of trial (months)

was a dialysate, dialysis membrane, or modality
of

hemodialysis

(such

as

hemodiaﬁltration

or

hemodialysis).
OUTCOMES AND OUTCOME MEASURES. The 1,743

deﬁnitions

(including

different

time

points

of

1–3

8

7

>3–6

24

20

>6–12

11

9

(e.g., troponin), with a median of 3.5 outcome mea-

measurement) were categorized into 236 measures

>12–24

28

23

sures reported per trial (range: 1 to 23). Across all

>24–48

23

19

trials, measures were assessed at 67 different time

>48

27

22

points with a range of 1 to 6 time points per trial.

Not stated

53

30

The number of measures was not associated with the

104

60

Dialysate

22

13

Mode of hemodialysis

26

15

Lifestyle

6

3

per trial (range: 1 to 16). Of the 26 outcomes, 15 (58%)

Other

5

3

were clinical, 10 (38%) were surrogates, and 1 (4%)

Dialysis machine

9

5

was

Coronary intervention

3

2

Illustration). The top 3 most frequently reported

Intervention type

sample size (Online Table 3). These measures were

Pharmacological/supplement

further grouped into 26 outcomes (e.g., cardiac
biomarkers), with a median of 2 outcomes reported

a

patient-reported

outcome:

pain

(Central

outcomes were serum biomarkers (excluding lipids
and traditional cardiac biomarkers; 52 trials [30%]),
(e.g., mean, median, proportion), and time point of

cardiovascular composite (52 trials [30%]), and serum

measurement (32).

lipid levels (41 trials [23%]).

We classiﬁed the outcomes into 236 measures (e.g.,

The number of measures for each outcome ranged

troponin) and then again into 26 outcome groups

from 1 to 61 (Figure 2). The serum biomarker outcome

(e.g., cardiac biomarker). A schema of the categori-

included 61 different biomarker measures; C-reactive

zation is provided in Online Figure 1, with an example

protein was the most frequently reported biomarker

in Online Table 2. Outcomes were further classiﬁed as

(34 trials [20%]), followed by homocysteine (8 trials

surrogate, clinical, or patient reported. A surrogate

[5%]).

outcome was deﬁned as a biochemical, imaging, or

included 11 composite measures, the 3 most frequent

other marker used as a substitute for a clinical

being a “cardiovascular composite” measure (e.g.,

outcome (33). A clinical outcome was deﬁned as a

“the cumulative rate of non-fatal MI [myocardial

medical

mortality,

infarction] or acute coronary syndrome, hospitaliza-

myocardial infarction, hospitalization) diagnosed by

tion for heart failure, nonfatal stroke or CV [cardio-

the clinician. Patient-reported outcomes were those

vascular] death”; 27 trials [16%]), a “cardiovascular

reported directly by patients regarding how they

event”

event

or

comorbidity

(e.g.,

The

(e.g.,

outcome

“rate

cardiovascular

of

cardiovascular

composite

events”;
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C E N T R A L IL L U ST R A T I O N Cardiovascular Outcomes in Hemodialysis: Proportion of Trials
Reporting Each Outcome (174 Trials, 26 Outcomes)

O’Lone, E. et al. J Am Coll Cardiol. 2018;71(24):2802–10.

Chart to show the 26 outcome groups determined from the 174 trials and the proportion of trials that reported them. The most frequently
reported outcomes were the surrogate outcome of serum biomarker and a cardiovascular composite outcome. Only 1 outcome was patient
reported. ACS ¼ acute coronary syndrome; ECG ¼ electrocardiography.
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F I G U R E 2 Number of Unique Measures Within Each Outcome Group

70

Outcome Measures (n)

60
50
40
30
20
10

Pain

Valve replacement

ECG

Heart failure

CV risk

Angina

Cardiac arrest

Heart rate

Functional assessment

MI & ACS

Autonomic function

Cardiac biomarker

Calcification

Thrombosis & embolism

PVD

Stroke

Arrhythmia

Lipid

Hospitalization

CV composite

Mortality

Cardiac function

Cardiac morphometry

Revascularization

Other serum biomarker

Vascular function & anatomy

0

Outcomes

Bar chart showing how the number of different measures contributed to each outcome excluding time points. There were 61 different
biomarkers measured in the outcome group other serum biomarkers and 32 different ways of measuring vascular function and anatomy.
ACS ¼ acute coronary syndrome; CV ¼ cardiovascular; ECG ¼ electrocardiography; MI ¼ myocardial infarction; PVD ¼ peripheral vascular
disease.

24 [14%] trials), and “cardiovascular event non-fatal”

MORTALITY

(4 trials [2%]) (Figure 2). The outcome serum lipid

outcomes were reported in 25 (14%) trials. Included in

levels had 10 different measures, the 3 most

the mortality outcome were 8 individual events, of

frequently reported being high-density lipoprotein

which sudden cardiac death was the most frequently

OUTCOMES. Cardiovascular

mortality

(26 trials [15%]), triglycerides (26 [15%] trials), and

reported (7 trials [4%]) (Online Figure 3). Composite

“total cholesterol” (21 [12%] trials).

mortality measures were assessed in 14 trials (8%),

Across the clinical outcomes, 13 different metrics

and 12 composite combinations were used (Figure 4).

were used to report the original deﬁnitions, including

Within the mortality outcome, the most frequently

number of events, rate of event, event free survival,

reported composite outcome measure was cardio-

and time to event. The methods of aggregation

vascular death, reported as a unique term in 16 trials

for the clinical outcomes included mean, median,

(9%) and also used in 5 mortality composite combi-

proportion, and proportional change.

nations (42%) (Figure 4).

CARDIOVASCULAR

composite

measure

components,

and

COMPOSITE

was
the

OUTCOME. Each

deconstructed

number

of

into

trials

its

TIME FOR MORE CONFIDENCE IN OUTCOMES

using

each component was analyzed as shown in Figure 3.

In contemporary clinical trials conducted in patients

Fifty-one trials (29%) used cardiovascular composite

on hemodialysis, a very large number of different

measures, and each trial used a range of 1 to 6

cardiovascular outcomes have been reported. Over a

these

third of these outcomes were classiﬁed as surrogates

51 trials, there were 50 unique composite combina-

rather than outcomes that would be expected to be

tions (Figure 3). The proportion of trials reporting

directly important to patients and clinicians (such as

each measure within the cardiovascular composite

sudden cardiac death, myocardial infarction), and

outcome is shown in Online Figure 2.

only 1 was patient reported (pain). The use of

different

composite

combinations.

Within
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F I G U R E 3 Cardiovascular Composite Matrix

Composites not further defined

Individual components of composites
Cardiac

Cardiovascular
Hosp Death Death Dx
US

Thrombosis

Hosp MACE Event Event SAE Morb Death Event US
US

all

NF

NC

DVT

PE

Heart failure

VA Embo Death Hosp

NF

MI, ACS, Angina

US

throm US

Fatal

Ang

ACS CHD Coron MI

unstab

NF Event US

MI

Stroke & TIA
MI

fatal hosp

MI

TIA

CVA Death Hem Hosp

Arrest/SCD
NF

US

Event

NF

CA

CA

CA

fatal

NF

resus

Revasc

Other

SCD CABG Cereb Coron US Hyper Hypo Hosp Periph
<+

tension

VF

cause

AS Trials using
AS
vasc cardiac event composite
(n)

event event

C1

1

C2

1

C3

1

C4

1

C5

1

C6

1

C7

1

C8

1

C9

1

C10

1

C11

1

C12

1

C13

1

C14

1

C15

1

C16

1

C17

1

C18

1

C19

1

C20

1

C21

1

C22

1

C23

1

C24

1

C25

1

C26

1

C27

1

C28

1

C29

1

C30

1

C31

1

C32

1

C33

1

C34

1

C35

1

C36

1
1

C37

1

C38
C39

1

C40

2

C41

2

C42

2

C43

2

C44

2

C45

2

C46

3
3

C47

3

C48
C49

3

C50

20

Total (n)

1

12

13

1

1

3

Number of trials using each composite

5

2

2

1

1

1

1

1

1

1

1

2

8

2

2

7

5

1

1

7

5

4

16

1

1

2

1

4

11

8

2

2

3

4

4

3

9

2

1

1

1

2

1

2

Number of times each component was used

Matrix to display the individual components of the 51 composite outcomes after deconstruction. The far right column tallies the number of trials that used each
composite, and the bottom row tallies the number of times each component was incorporated into a composite. Myocardial infarction was the most frequently used
component in a composite, and most composite combinations were only used in 1 or 2 trials. ACS ¼ acute coronary syndrome; Ang ¼ angina; AS ¼ atherosclerotic;
CA ¼ cardiac arrest; Cereb ¼ cerebrovascular; CHD ¼ coronary heart disease; Coron ¼ coronary; CVA ¼ cerebrovascular accident; DVT ¼ deep vein thrombosis;
Dx ¼ disease; Embol ¼ embolism; Hem ¼ hemorrhagic; Hosp ¼ hospitalization; MACE ¼ major adverse cardiovascular event; MI ¼ myocardial infarction;
Morb ¼ morbidity; NC ¼ noncoronary; NF ¼ nonfatal; PE ¼ pulmonary embolism; Periph ¼ peripheral; resus ¼ resuscitation; Revasc ¼ revascularization; SAE ¼ serious
adverse event; throm ¼ thrombosis; TIA ¼ transient ischemic attack; US ¼ unspeciﬁed; VA ¼ vascular access; vasc ¼ vascular; VF ¼ cardiac arrhythmia.

surrogate outcomes is probably a function of the

serum biomarkers measured and more than 30

small sample sizes of most of the trials identiﬁed. Use

different ways to measure vascular function and

of composite outcomes was common, being used in a

anatomy. Heterogeneity was evident at multiple

third of the trials, but each trial used different com-

levels, including deﬁnition of the measurement, the

ponents to make up its composites, and they were

metric, the method of aggregation, and the time point

often ill deﬁned, making comparisons across studies

of measurement of the outcome measure. This het-

problematic. This echoes the ﬁndings in other pop-

erogeneity is not unique to the hemodialysis popu-

ulations regarding the complexity and discord within

lation. In a review of outcomes in cardiac arrest trials,

composite outcomes (18,29). A review of composite

more than 160 individual outcomes were reported,

outcomes within cardiovascular trials found that the

including 39 different measures of survival (35).

components of composite endpoints varied widely in

This review highlights the urgent need to develop a

terms of their importance to patients and in the

core outcome set in hemodialysis trials. Recently, the

magnitude of their effect of the intervention. This can

Standardized Outcomes in Nephrology initiative was

give rise to misleading interpretations regarding the

established, which has used validated consensus

impact of treatment (18).

methodology to bring together patients and health

The variety of measures used to assess each

care professionals to identify critically important

outcome was substantial, particularly among the

outcomes in hemodialysis (36–38). CVD was identiﬁed

surrogate outcomes, with more than 60 different

as a core outcome domain (along with vascular
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F I G U R E 4 Mortality Composite Matrix

Composites not further defined

Individual components

Vascular

CV

CHD

Cardiac

Cardiac

death

Death

death

death

arrest

SCD

Cardiac

Acute MI

arrhythmia

Heart

Stroke Trials using

Stroke Stroke

failure US

ischemic

hem

composite
(n)

Composites

C1

2

C2

2

C3

2

C4

16

C5

4

C6

1

C7

1

C8

1

C9

1

C10

1

C11

1

C12
Total (n)*

1
2

5

1

3

1

Number of trials using each composite

2

2

3

3

4

1

1

*number of times each component is used

Matrix showing the individual components of the 12 composites after deconstruction. The far right column tallies the number of trials that used each composite, and the
bottom row tallies the number of times each component was incorporated into a composite. The composite cardiovascular death was used in 16 trials but was not
further deﬁned. CV ¼ cardiovascular; SCD ¼ sudden cardiac death; other abbreviations as in Figures 2 and 3.

access, fatigue, and mortality). The next phase of the
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